Quick Answer
Biofrontera Inc. reported Total Revenue of $41.70 million for fiscal year 2025.
Biofrontera Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $41.70M +11.7% |
$37.32M +9.5% |
$34.07M +18.8% |
$28.67M +19.0% |
$24.10M +27.9% |
$18.85M |
| Revenue (ASC 606) | $41.70M +11.7% |
$37.32M +9.5% |
$34.07M +18.8% |
$28.67M +19.0% |
$24.10M +27.9% |
$18.85M |
| Net Income | -$10.54M +40.7% |
-$17.76M +11.8% |
-$20.13M -3045.5% |
-$640.0K +98.3% |
-$37.71M -243.3% |
-$10.99M |
| Diluted EPS | -$1.04 +67.7% |
-$3.22 +75.3% |
-$13.02 -2034.4% |
-$0.61 | — | — |
| Total Assets | $28.56M +29.2% |
$22.10M -20.9% |
$27.93M -45.1% |
$50.88M -4.4% |
$53.22M +120.5% |
$24.14M |
| Cash and Equivalents | $6.39M +8.2% |
$5.91M +339.7% |
$1.34M -92.2% |
$17.21M -29.9% |
$24.55M +203.8% |
$8.08M |
| Stockholders Equity | $10.48M +136.4% |
$4.43M -7.5% |
$4.79M -79.9% |
$23.88M +110.6% |
$11.34M +94.5% |
$5.83M +119.3% |
| R&D Expense | $3.72M +78.0% |
$2.09M +2613.0% |
$77.0K | — | — | — |
| Operating Income | -$11.35M +34.1% |
-$17.21M +24.1% |
-$22.68M -22.0% |
-$18.58M +26.3% |
-$25.20M -162.3% |
-$9.61M |
| Shares Outstanding | 11.65M +31.3% |
8.87M +484.7% |
1.52M +13.7% |
1.33M -92.2% |
17.10M +113.8% |
8.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $6.99M | -22.5% | -22.6% |
| Revenue (ASC 606) | September 30, 2025 | $6.99M | -22.5% | -22.6% |
| Net Income | September 30, 2025 | -$6.65M | -17.3% | -24.9% |
| Diluted EPS | September 30, 2025 | -$0.62 | +36.7% | -8.8% |
| Total Assets | September 30, 2025 | $15.41M | -16.7% | -23.5% |
| Cash and Equivalents | September 30, 2025 | $3.42M | +18.9% | -52.8% |
| Stockholders Equity | September 30, 2025 | -$2.58M | -146.7% | +44.7% |
| R&D Expense | September 30, 2025 | $854.0K | +27.7% | -1.8% |
| Operating Income | September 30, 2025 | -$6.28M | -26.6% | -23.6% |
| Shares Outstanding | September 30, 2025 | 11.65M | +78.4% | +14.9% |
- Biofrontera Inc. reported Total Revenue of $41.70 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +11.7% in Total Revenue compared to the prior fiscal year.
- Biofrontera Inc. reported Revenue (ASC 606) of $41.70 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +11.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Biofrontera Inc. reported Net Income of -$10.54 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +40.7% in Net Income compared to the prior fiscal year.
- Biofrontera Inc. reported Diluted EPS of $1.04 per share (loss) for fiscal year 2025.
- Biofrontera Inc. showed an increase of +67.7% in Diluted EPS compared to the prior fiscal year.
- Biofrontera Inc. reported Total Assets of $28.56 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +29.2% in Total Assets compared to the prior fiscal year.
- Biofrontera Inc. reported Cash and Equivalents of $6.39 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +8.2% in Cash and Equivalents compared to the prior fiscal year.
- Biofrontera Inc. reported Stockholders Equity of $10.48 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +136.4% in Stockholders Equity compared to the prior fiscal year.
- Biofrontera Inc. reported R&D Expense of $3.72 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +78.0% in R&D Expense compared to the prior fiscal year.
- Biofrontera Inc. reported Operating Income of -$11.35 million for fiscal year 2025.
- Biofrontera Inc. showed an increase of +34.1% in Operating Income compared to the prior fiscal year.
- Biofrontera Inc. reported Shares Outstanding of 11.65 million shares for fiscal year 2025.
- Biofrontera Inc. showed an increase of +31.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: